ARCHIVES

NTP Committee Accepts Industry Positions On Policy To Separate Figures for Benign, Malignant Lesions

This article is from The Cancer Letter archive.

Vol. 06 No. 44 | November 7, 1980

Download PDF Visit The Full Archive

Related Articles

In Brief: $100 Million Being Spent On Interferon In U.S., Rauscher Says; DeVita; Criticism Deserved

April 4, 1980

Recompetition of $1.9 Mil. Primate Contract Approved

November 15, 1985

“Harm-Reduction” Products No Proven, IOM Report Says.

March 2, 2001

Georgetown Sponsors Oncology Agent Development Meeting

February 21, 2003

Cuts Claimed to Displace “Millions” of Patients Yet None Seem to Complain. Why Not?

April 25, 2013

“Imaginary Treatments,” “Wonderful Cures”

June 6, 1997